Acute Lung Injury Market, Size, Share, Opportunities and Forecast, 2020-2027

SKU: DPH138 | Last Updated On: Sep 08 2020 | No. of Pages: 223 | Available Formats

> Global Acute Lung Injury Market Expected to reach a high CAGR of 5.8% By 2027: DataM Intelligence

Global Acute Lung Injury Market is Segment By Therapy (Mechanical ventilation, Pharmacotherapy, Fluid management), By End-user (Hospitals, Clinics,others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2020-2027

 

Market Overview

The Global Acute Lung Injury Market is expected to grow at a CAGR of 5.8% during the forecasting period (2020-2027).

Acute lung injury is a severe condition caused by acute hypoxemic respiratory failure. It is a crucial source of mortality and morbidity in critically ill patients without any evidence of hydrostatic pulmonary oedema. Symptoms seen in acute lung injury include severe shortness of breath, confusion, low blood pressure, and extreme tiredness.

Market Overview

 

Source: DataM Intelligence Analysis (2019)

Market Dynamics

The major driving forces are the growing prevalence of lung-related diseases, increase in geriatric population, growth in awareness about health diagnostics, and technological advancements.

The rising prevalence of lung-related diseases is expected to propel market growth. For instance, the Global Burden of Disease Study reported a prevalence of 251 million cases of COPD globally in 2016. WHO stated that about 65 million people suffer from the chronic obstructive pulmonary disease (COPD) and 3 million dies from it each year, making it the third leading cause of death worldwide. Around 334 million people will have asthma, the most common chronic disease of childhood, affecting 14% of all children worldwide. Pneumonia kills millions of people yearly and is a leading cause of death among children under five years old.

The growing geriatric population is expected to boost the market growth. Many nations are facing challenges owing to the ongoing and the increasing demographic shift in age among the people. As per the Department of Economic and Social Affairs Population Division of United Nation, 2017, the world's population of 60 years will double and those of 80 years old will triple in the next 30 years. As per the World Health Organization, the number of people of 65 years or older is expected to increase to around 1.5 billion in 2050, with most of the increase in the developing countries. Thus, the increasing geriatric population, who are more prone to chronic illness, is driving the market.

The presence of government initiatives is expected to boost market growth over the forecast period. For instance, the World Health Organization (WHO) launched the Global Alliance against Respiratory Diseases (GARD) to bring the combined knowledge of the national and international organizations, institutions and the agencies to improve the lives of nearly 1 billion people affected by chronic and acute respiratory diseases.

The presence of an increased number of research and development activities is expected to boost the market. For instance,

University

Study Title

Phase

Anticipated launch

Damanhour University

Role of ascorbic acid infusion in critically ill patients with transfusion related acute lung injury

Phase 2

February 2021

National Jewish Health

Macrophage programming in acute lung injury

Not applicable

March 2023

However, the complications associated with the therapies, high cost of therapies, low adoption rate of digital radiography and the portable spirometers for diagnosing the condition impede the market growth.

The complications associated with the therapies is likely to hamper the market growth. For instance, Mechanical ventilation is often a life-saving intervention but carries potential complications, including pneumothorax, alveolar damage, ventilator-associated pneumonia, airway injury, and ventilator-associated tracheobronchitis.

Market Segmentation

Based on the therapy, the global acute lung injury market is segmented into pharmacotherapy, mechanical ventilation, fluid management, and others.

The mechanical ventilation segment is expected to grow at a high rate over the forecast period, as it is the primary choice for the supportive treatment of patients with acute lung injury (ALI). It includes the delivery of air/oxygen at tidal volumes and frequencies to be enough to reduce the pressure on breathing with simultaneous progress in oxygenation. In case, if a patient requires lengthy mechanical ventilation, the tracheotomy process is suggested that permits stable airway, mobilization, and ease out the deterring of mechanical ventilation. Though extracorporeal membrane oxygenation (ECMO) is not used extensively, it is in function for some instances.

 Source: DataM Intelligence Analysis (2019)

Geographical Analysis

Geographically, the global acute lung injury market is segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

North America is dominating the global acute lung injury market in 2018 and is estimated to hold significant market size over the forecast period (2020-2027) owing to the rising prevalence of acute lung injuries in the region.

The rising prevalence of acute lung injuries is expected to boost market growth over the forecast period. For instance, according to the National Heart, Lung, and Blood Institute, 79 people per 100,000 population per year developed acute lung injury (ALI), and 59 of these met the criteria for the more severe form of acute respiratory distress syndrome. The death rate of acute lung injury patients was around 38.5 %. Using the US census and assuming the same frequency throughout the country, 190,600 people per year develop ALI, and 74,500 dies off, or with, the disease in the US. Thus, the rising prevalence of acute lung injuries is driving the market.

Source: DataM Intelligence Analysis (2019)

Competitive Landscape

The key players operating in the global acute lung injury market are Altor BioScience Corporation, GlaxoSmithKline Plc, Commence Bio, Inc., CompleGen, Inc., Histocell S.L., Windtree Therapeutics, Inc., Navigen Pharmaceuticals, Inc., Silence Therapeutics plc, Quark Pharmaceuticals, Inc., and Ono Pharmaceutical Co., Ltd.

The key players are adopting various strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, which are contributing to the growth of the acute lung injury market globally. For instance,

On September 6, 2019, Windtree Therapeutics announced the publication of results of lung deposition study of aerosolized Lucinactant.

Why Purchase the Report?

  • Visualize the composition of the global acute lung injury market across each therapy, and end-user highlighting the key commercial assets and players.
  • Identify commercial opportunities in the global acute lung injury market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of the global acute lung injury market-level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Type mapping in excel for the key Services of all major market players.

The Global Acute Lung Injury Market report would provide access to an approx, 62 market data tables, 51 figures, and 220 pages.

Target Audience:

  • Equipment Suppliers/ Buyers
  • Type Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

 

Related Reports

Airway Stent/Lung Stent Market

 

 

 

Table of Content

  1. Acute Lung Injury Market Methodology and Scope

    1. Research Methodology
    2. Research Objective and Scope of the Report
  2. Acute Lung Injury Market – Market Definition and Overview

  3. Acute Lung Injury Market – Executive Summary

    1. Market Snippet by Therapy
    2. Market Snippet by End-user
  4. Acute Lung Injury Market Dynamics

    1. Market Impacting Factors
    2. Drivers
      1. The rising prevalence of lung-related diseases
      2. The growing geriatric population
    3. Restraints
      1. The complications associated with therapies
    4. Opportunity
    5. Impact Analysis
  5. Acute Lung Injury Market – Industry Analysis

    1. Porter's Five Forces Analysis
    2. Regulatory Analysis
    3. Supply Chain Analysis
    4. Pricing Analysis
    5. Unmet Needs
  6. Acute Lung Injury Market - By Therapy

    1. Introduction
      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy
      2. Market Attractiveness Index, By Therapy Segment
    2. Mechanical ventilation*
      1. Introduction
      2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2018-2026
    3. Pharmacotherapy
    4. Fluid management
    5. Others
  7. Acute Lung Injury Market - By End-user

    1. Introduction
      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
      2. Market Attractiveness Index, By End-user Segment
    2. Hospitals*
      1. Introduction
      2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2018-2026
    3. Clinics
    4. Others
  8. Acute Lung Injury Market - By Region

    1. Introduction
      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
      2. Market Attractiveness Index, By Region
    2. North America
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. The U.S.
        2. Canada
        3. Mexico
    3. Europe
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. Germany
        2. The U.K.
        3. France
        4. Italy
        5. Spain
        6. Rest of Europe
    4. South America
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. Brazil
        2. Argentina
        3. Rest of South America
    5. Asia Pacific
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. China
        2. India
        3. Japan
        4. Australia
        5. Rest of Asia Pacific
    6. The Middle East and Africa
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
  9. Acute Lung Injury Market Competitive Landscape

    1. Competitive Scenario
    2. Market Positioning/Share Analysis
    3. Mergers and Acquisitions Analysis
  10. Acute Lung Injury Market Company Profiles

    1. Altor BioScience Corporation*
      1. Company Overview
      2. Product Portfolio and Description
      3. Key Highlights
      4. Financial Overview
    2. GlaxoSmithKline Plc
    3. Commence Bio, Inc.
    4. CompleGen, Inc.
    5. Histocell S.L.
    6. Windtree Therapeutics, Inc.
    7. Navigen Pharmaceuticals, Inc.
    8. Silence Therapeutics plc
    9. Quark Pharmaceuticals, Inc.
    10. Ono Pharmaceutical Co., Ltd. (LIST NOT EXHAUSTIVE)
  11. Acute Lung Injury Market – Premium Insights

  12. Acute Lung Injury Market – Data-M

    1. Appendix
    2. About Us and Services
    3. Contact Us

List of Tables & Figures

LIST OF TABLES

TABLE 01 GLOBAL ACUTE LUNG INJURY MARKET VALUE, BY THERAPY, 2018, 2022 & 2027 ($ MILLION)

TABLE 02 GLOBAL ACUTE LUNG INJURY MARKET VALUE, BY END-USER, 2018, 2022 & 2027 ($ MILLION)

TABLE 03 GLOBAL ACUTE LUNG INJURY MARKET VALUE, BY REGION, 2018, 2022 & 2027 ($ MILLION)

TABLE 04 GLOBAL ACUTE LUNG INJURY MARKET VALUE, BY COUNTRY, 2018, 2022 & 2027 ($ MILLION)

TABLE 05 GLOBAL ACUTE LUNG INJURY MARKET VALUE, BY THERAPY, 2018, 2022 & 2027 ($ MILLION)

TABLE 06 GLOBAL ACUTE LUNG INJURY MARKET VALUE, BY THERAPY, 2017-2027 ($ MILLION)

TABLE 07 GLOBAL ACUTE LUNG INJURY MARKET VALUE, BY END-USER, 2018, 2022 & 2027 ($ MILLION)

TABLE 08 GLOBAL ACUTE LUNG INJURY MARKET VALUE, BY END-USER, 2017-2027 ($ MILLION)

TABLE 09 GLOBAL ACUTE LUNG INJURY MARKET VALUE, BY REGION, 2018, 2022 & 2027 ($ MILLION)

TABLE 10 GLOBAL ACUTE LUNG INJURY MARKET VALUE, BY REGION, 2017-2027 ($ MILLION)

TABLE 11 GLOBAL ACUTE LUNG INJURY MARKET VALUE, BY COUNTRY, 2018, 2022 & 2027 ($ MILLION)

TABLE 12 GLOBAL ACUTE LUNG INJURY MARKET VALUE, BY COUNTRY, 2017-2027 ($ MILLION)

TABLE 13 NORTH AMERICA ACUTE LUNG INJURY MARKET VALUE, BY THERAPY, 2017-2027 ($ MILLION)

TABLE 14 NORTH AMERICA ACUTE LUNG INJURY MARKET VALUE, BY END-USER, 2017-2027 ($ MILLION)

TABLE 15 NORTH AMERICA ACUTE LUNG INJURY MARKET VALUE, BY REGION, 2017-2027 ($ MILLION)

TABLE 16 NORTH AMERICA ACUTE LUNG INJURY MARKET VALUE, BY COUNTRY, 2017-2027 ($ MILLION)

TABLE 17 SOUTH AMERICA ACUTE LUNG INJURY MARKET VALUE, BY THERAPY, 2017-2027 ($ MILLION)

TABLE 18 SOUTH AMERICA ACUTE LUNG INJURY MARKET VALUE, BY END-USER, 2017-2027 ($ MILLION)

TABLE 19 SOUTH AMERICA ACUTE LUNG INJURY MARKET VALUE, BY REGION, 2017-2027 ($ MILLION)

TABLE 20 SOUTH AMERICA ACUTE LUNG INJURY MARKET VALUE, BY COUNTRY, 2017-2027 ($ MILLION)

TABLE 21 EUROPE ACUTE LUNG INJURY MARKET VALUE, BY THERAPY, 2017-2027 ($ MILLION)

TABLE 22 EUROPE ACUTE LUNG INJURY MARKET VALUE, BY END-USER, 2017-2027 ($ MILLION)

TABLE 23 EUROPE ACUTE LUNG INJURY MARKET VALUE, BY REGION, 2017-2027 ($ MILLION)

TABLE 24 EUROPE ACUTE LUNG INJURY MARKET VALUE, BY COUNTRY, 2017-2027 ($ MILLION)

TABLE 25 ASIA-PACIFIC ACUTE LUNG INJURY MARKET VALUE, BY THERAPY, 2017-2027 ($ MILLION)

TABLE 26 ASIA-PACIFIC ACUTE LUNG INJURY MARKET VALUE, BY END-USER, 2017-2027 ($ MILLION)

TABLE 27 ASIA-PACIFIC ACUTE LUNG INJURY MARKET VALUE, BY REGION, 2017-2027 ($ MILLION)

TABLE 28 ASIA-PACIFIC ACUTE LUNG INJURY MARKET VALUE, BY COUNTRY, 2017-2027 ($ MILLION)

TABLE 29 MIDDLE EAST & AFRICA ACUTE LUNG INJURY MARKET VALUE, BY THERAPY, 2017-2027 ($ MILLION)

TABLE 30 MIDDLE EAST & AFRICA ACUTE LUNG INJURY MARKET VALUE, BY END-USER, 2017-2027 ($ MILLION)

TABLE 31 MIDDLE EAST & AFRICA ACUTE LUNG INJURY MARKET VALUE, BY REGION, 2017-2027 ($ MILLION)

TABLE 32 MIDDLE EAST & AFRICA ACUTE LUNG INJURY MARKET VALUE, BY COUNTRY, 2017-2027 ($ MILLION)

TABLE 33 ALTOR BIOSCIENCE CORPORATION: OVERVIEW

TABLE 34 ALTOR BIOSCIENCE CORPORATION: PRODUCT PORTFOLIO

TABLE 35 ALTOR BIOSCIENCE CORPORATION: KEY DEVELOPMENTS

TABLE 36 GLAXOSMITHKLINE PLC: OVERVIEW

TABLE 37 GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO

TABLE 38 GLAXOSMITHKLINE PLC: KEY DEVELOPMENTS

TABLE 39 COMMENCE BIO, INC.: OVERVIEW

TABLE 40 COMMENCE BIO, INC.: PRODUCT PORTFOLIO

TABLE 41 COMMENCE BIO, INC.: KEY DEVELOPMENTS

TABLE 42 COMPLEGEN, INC.: OVERVIEW

TABLE 43 COMPLEGEN, INC.: PRODUCT PORTFOLIO

TABLE 44 COMPLEGEN, INC.: KEY DEVELOPMENTS

TABLE 45 HISTOCELL S.L.: OVERVIEW

TABLE 46 HISTOCELL S.L.: PRODUCT PORTFOLIO

TABLE 47 HISTOCELL S.L.: KEY DEVELOPMENTS

TABLE 48 WINDTREE THERAPEUTICS, INC.: OVERVIEW

TABLE 49 WINDTREE THERAPEUTICS, INC.: PRODUCT PORTFOLIO

TABLE 50 WINDTREE THERAPEUTICS, INC.: KEY DEVELOPMENTS

TABLE 51 NAVIGEN PHARMACEUTICALS, INC.: OVERVIEW

TABLE 52 NAVIGEN PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO

TABLE 53 NAVIGEN PHARMACEUTICALS, INC.: KEY DEVELOPMENTS

TABLE 54 SILENCE THERAPEUTICS PLC: OVERVIEW

TABLE 55 SILENCE THERAPEUTICS PLC: PRODUCT PORTFOLIO

TABLE 56 SILENCE THERAPEUTICS PLC: KEY DEVELOPMENTS

TABLE 57 QUARK PHARMACEUTICALS, INC.: OVERVIEW

TABLE 58 QUARK PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO

TABLE 59 QUARK PHARMACEUTICALS, INC.: KEY DEVELOPMENTS

TABLE 60 ONO PHARMACEUTICAL CO., LTD.: OVERVIEW

TABLE 61 ONO PHARMACEUTICAL CO., LTD.: PRODUCT PORTFOLIO

TABLE 62 ONO PHARMACEUTICAL CO., LTD.: KEY DEVELOPMENTS

 

 LIST OF FIGURES

FIGURE 01 GLOBAL ACUTE LUNG INJURY MARKET SHARE, BY THERAPY, 2018 & 2027 (%)

FIGURE 02 GLOBAL ACUTE LUNG INJURY MARKET SHARE, BY END-USER, 2018 & 2027 (%)

FIGURE 03 GLOBAL ACUTE LUNG INJURY MARKET SHARE, BY REGION, 2018 & 2027 (%)

FIGURE 04 GLOBAL ACUTE LUNG INJURY MARKET SHARE, BY COUNTRY, 2018 & 2027 (%)

FIGURE 05 GLOBAL ACUTE LUNG INJURY MARKET VALUE, 2017-2027 ($ MILLION)

FIGURE 06 GLOBAL ACUTE LUNG INJURY MARKET Y-O-Y GROWTH, BY THERAPY, 2018-2027 (%)

FIGURE 07 MECHANICAL VENTILATION: GLOBAL ACUTE LUNG INJURY MARKET VALUE, 2017-2027 ($ MILLION)

FIGURE 08 PHARMACOTHERAPY: GLOBAL ACUTE LUNG INJURY MARKET VALUE, 2017-2027 ($ MILLION)

FIGURE 09 FLUID MANAGEMENT: GLOBAL ACUTE LUNG INJURY MARKET VALUE, 2017-2027 ($ MILLION)

FIGURE 10 OTHERS: GLOBAL ACUTE LUNG INJURY MARKET VALUE, 2017-2027 ($ MILLION)

FIGURE 11 GLOBAL ACUTE LUNG INJURY MARKET Y-O-Y GROWTH, BY END-USER, 2018-2027 (%)

FIGURE 12 HOSPITALS: GLOBAL ACUTE LUNG INJURY MARKET VALUE, 2017-2027 ($ MILLION)

FIGURE 13 CLINICS: GLOBAL ACUTE LUNG INJURY MARKET VALUE, 2017-2027 ($ MILLION)

FIGURE 14 OTHERS: GLOBAL ACUTE LUNG INJURY MARKET VALUE, 2017-2027 ($ MILLION)

FIGURE 15 GLOBAL ACUTE LUNG INJURY MARKET Y-O-Y GROWTH, BY REGION, 2018-2027 (%)

FIGURE 16 GLOBAL ACUTE LUNG INJURY MARKET Y-O-Y GROWTH, BY COUNTRY, 2018-2027 (%)

FIGURE 17 NORTH AMERICA ACUTE LUNG INJURY MARKET VALUE, 2017-2027 ($ MILLION)

FIGURE 18 NORTH AMERICA ACUTE LUNG INJURY MARKET SHARE, BY THERAPY, 2018 & 2027 (%)

FIGURE 19 NORTH AMERICA ACUTE LUNG INJURY MARKET SHARE, BY END-USER, 2018 & 2027 (%)

FIGURE 20 NORTH AMERICA ACUTE LUNG INJURY MARKET SHARE, BY REGION, 2018 & 2027 (%)

FIGURE 21 NORTH AMERICA ACUTE LUNG INJURY MARKET SHARE, BY COUNTRY, 2018 & 2027 (%)

FIGURE 22 SOUTH AMERICA ACUTE LUNG INJURY MARKET VALUE, 2017-2027 ($ MILLION)

FIGURE 23 SOUTH AMERICA ACUTE LUNG INJURY MARKET SHARE, BY THERAPY, 2018 & 2027 (%)

FIGURE 24 SOUTH AMERICA ACUTE LUNG INJURY MARKET SHARE, BY END-USER, 2018 & 2027 (%)

FIGURE 25 SOUTH AMERICA ACUTE LUNG INJURY MARKET SHARE, BY REGION, 2018 & 2027 (%)

FIGURE 26 SOUTH AMERICA ACUTE LUNG INJURY MARKET SHARE, BY COUNTRY, 2018 & 2027 (%)

FIGURE 27 EUROPE ACUTE LUNG INJURY MARKET VALUE, 2017-2027 ($ MILLION)

FIGURE 28 EUROPE ACUTE LUNG INJURY MARKET SHARE, BY THERAPY, 2018 & 2027 (%)

FIGURE 29 EUROPE ACUTE LUNG INJURY MARKET SHARE, BY END-USER, 2018 & 2027 (%)

FIGURE 30 EUROPE ACUTE LUNG INJURY MARKET SHARE, BY REGION, 2018 & 2027 (%)

FIGURE 31 EUROPE ACUTE LUNG INJURY MARKET SHARE, BY COUNTRY, 2018 & 2027 (%)

FIGURE 32 ASIA-PACIFIC ACUTE LUNG INJURY MARKET VALUE, 2017-2027 ($ MILLION)

FIGURE 33 ASIA-PACIFIC ACUTE LUNG INJURY MARKET SHARE, BY THERAPY, 2018 & 2027 (%)

FIGURE 34 ASIA-PACIFIC ACUTE LUNG INJURY MARKET SHARE, BY END-USER, 2018 & 2027 (%)

FIGURE 35 ASIA-PACIFIC ACUTE LUNG INJURY MARKET SHARE, BY REGION, 2018 & 2027 (%)

FIGURE 36 ASIA-PACIFIC ACUTE LUNG INJURY MARKET SHARE, BY COUNTRY, 2018 & 2027 (%)

FIGURE 37 MIDDLE EAST & AFRICA ACUTE LUNG INJURY MARKET VALUE, 2017-2027 ($ MILLION)

FIGURE 38 MIDDLE EAST & AFRICA ACUTE LUNG INJURY MARKET SHARE, BY THERAPY, 2018 & 2027 (%)

FIGURE 39 MIDDLE EAST & AFRICA ACUTE LUNG INJURY MARKET SHARE, BY END-USER, 2018 & 2027 (%)

FIGURE 40 MIDDLE EAST & AFRICA ACUTE LUNG INJURY MARKET SHARE, BY REGION, 2018 & 2027 (%)

FIGURE 41 MIDDLE EAST & AFRICA ACUTE LUNG INJURY MARKET SHARE, BY COUNTRY, 2018 & 2027 (%)

FIGURE 42 ALTOR BIOSCIENCE CORPORATION: FINANCIALS

FIGURE 43 GLAXOSMITHKLINE PLC: FINANCIALS

FIGURE 44 COMMENCE BIO, INC.: FINANCIALS

FIGURE 45 COMPLEGEN, INC.: FINANCIALS

FIGURE 46 HISTOCELL S.L.: FINANCIALS

FIGURE 47 WINDTREE THERAPEUTICS, INC.: FINANCIALS

FIGURE 48 NAVIGEN PHARMACEUTICALS, INC.: FINANCIALS

FIGURE 49 SILENCE THERAPEUTICS PLC: FINANCIALS

FIGURE 50 QUARK PHARMACEUTICALS, INC.: FINANCIALS

FIGURE 51 ONO PHARMACEUTICAL CO., LTD.: FINANCIALS

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report



Get your FREE SAMPLE PROPOSAL with a single click!

linkedinpinterest